Daflavon

Quick links to important sections

Daflavon

Method of action: Angioprotective, Venotonic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Daflavon

Property Description
Active Ingredients Diosmin and Hesperidin
Form Oral Solid Formulation (Tablet)
Pharmacological Class Phlebotonic Agent / Venoactive Drug
General Purpose Supports vascular tone and microcirculation integrity
Origin Derived from Natural Citrus Bioflavonoids (Semi-synthetic Diosmin)

Daflavon is formally classified as a Phlebotonic agent and a Venoactive drug, constituting a pharmaceutical combination product designed to provide systemic support to the vascular system. This medicine belongs to the Flavonoid class and is recognized for its actions in improving the function and integrity of the veins and microcirculation. It is supplied as an oral solid formulation, typically a tablet, intended for oral administration.

The core active component of Daflavon is the Micronized Purified Flavonoid Fraction (MPFF), composed primarily of two active ingredients: Diosmin and Hesperidin. These compounds are derived from natural Citrus bioflavonoids; however, Diosmin is typically produced via a semi-synthetic route for enhanced standardization and purity. The formulation is micronized, a key feature that is clinically recognized for enhancing intestinal absorption and bioavailability, distinguishing it from standard, non-micronized powders. This micronization strategy improves the body's ability to utilize the active compounds effectively.

The general therapeutic purpose of this venoactive drug is to enhance venous tone and stabilize the integrity of the microcirculation. This is achieved by the physiological actions of the flavonoids, which help to increase capillary resistance and concurrently reduce capillary hyperpermeability. These flavonoids are used for addressing symptoms related to venous circulation disturbances. These combined actions are generally useful for supporting overall venous health by improving lymphatic drainage and mitigating symptoms, such as the feeling of heaviness or fatigue, that are broadly associated with compromised fluid return.

What side effects are possible with Daflavon?

Possible Side Effects and Safety Information

Daflavon (micronized purified flavonoid fraction) is generally associated with a favorable safety profile, with most documented adverse reactions being of mild intensity. The officially classified side effects are categorized by the body system affected and their reported frequency.

System-Organ Class Common (1 in 10 to 1 in 100) Rare (1 in 1,000 to 1 in 10,000) Frequency Not Known
Gastrointestinal Disorders Diarrhoea, dyspepsia, nausea, vomiting Colitis (Uncommon) Abdominal pain
Nervous System Dizziness, headache, malaise
Skin & Subcutaneous Tissue Rash, pruritus (itching), urticaria (hives) Isolated face, eyelid, or lip oedema. Exceptionally, Quincke's oedema (angioedema).

Serious Adverse Reactions

Severe manifestations of skin and subcutaneous tissue disorders, such as isolated oedema of the face, eyelids, or lips, and, exceptionally, the life-threatening condition known as Quincke's oedema (rapid swelling of tissues that may obstruct breathing), have been reported with a frequency that cannot be estimated from the available data. The drug is contraindicated in patients with known hypersensitivity to the active substance or any of its components.

Population-Specific Considerations

  • Pregnancy and Breast-feeding: As a precautionary measure, use during pregnancy is typically advised to be avoided due to the limited amount of human data, although animal studies do not indicate reproductive toxicity. A decision must be made by a healthcare provider regarding continuing the medication or discontinuing breast-feeding, as it is unknown whether the active substance is excreted in human milk.
  • Paediatric Population: Safety and efficacy have not been established in children and adolescents under 18 years of age.

In cases of acute haemorrhoidal attack, the official guidance is that treatment must be short-term, and if symptoms do not subside promptly, a medical examination should be performed. The overall safety profile suggests that Daflavon has negligible influence on the ability to drive and use machines.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is based on official government regulatory documents detailing the known risks and required actions in cases of overexposure to Daflavon.

Documented Overdose Presentations

Official regulatory experience with Daflavon overdose is limited. The most frequently reported signs following ingestion of excessive amounts are generally non-severe and affect the digestive system and skin.

System Affected Documented Manifestations
Gastrointestinal Diarrhea, nausea, abdominal pain
Skin/Subcutaneous Pruritus (itching), rash

Required Emergency Actions

When to Seek Immediate Medical Help

If more Daflavon has been taken than directed, it is an official requirement to contact a doctor or pharmacist immediately for guidance.

Management of Overdose

Official prescribing information states that the management of any potential overdose should consist solely of the treatment of the clinical symptoms present. There are no specific complex interventions or antidotes officially indicated for Daflavon overexposure. The documented manifestations do not typically include life-threatening outcomes, but immediate professional consultation is mandated if overexposure is suspected.

Therapeutic Uses of Daflavon

What Daflavon Treats: Main Uses and Benefits

Daflavon is an adjunctive therapy designed to offer supportive symptomatic management across various clinical scenarios marked by temporary functional strain or discomfort. It is applied in addressing symptom clusters that can appear suddenly or intensify over time, contributing to improved overall day-to-day comfort and stability.

This medication is commonly used for treating symptoms associated with conditions involving venous circulation (such as heavy legs, pain, and restless legs) and symptoms during acute hemorrhoidal episodes.


Easing Episodic Symptom Discomfort

Daflavon is commonly used in situations involving episodic or fluctuating symptom patterns that may create noticeable interference with daily stability. It helps address groups of symptoms that may become temporarily overwhelming, offering short-term supportive relief during phases of increased patient discomfort. It plays a role in managing the stabilization of acute symptoms linked to systemic imbalance.


Supporting Functional Stability During Symptom Flares

This medication is applicable in conditions marked by periods of heightened physiological tension where symptoms cluster into patterns requiring supportive management. Daflavon offers symptomatic relief that helps patients cope more steadily with difficult episodes. It contributes to maintaining a sense of stability, generally assisting with maintaining functional stability and contributing to easing the overall symptom load of disruptive symptom manifestations.

Quick Fact: Supportive Management for Symptoms Related to Systemic Imbalance


Management of Acute and Recurrent Symptom Manifestations

Daflavon is considered relevant in clinical settings where symptoms form part of acute or recurrent episodes leading to temporary functional strain. It is often applied during these phases, providing support that may assist with easing the intensity of symptoms linked to irritative states. This supports the availability of appropriate symptomatic assistance when symptoms become more noticeable and require supportive attention.

Regulatory References

  1. Rwanda FDA Patient Information Leaflet

Eligibility and Restrictions for Use

The eligibility for using Daflavon (Micronised Purified Flavonoid Fraction) is determined by specific exclusions and precautions detailed in official regulatory documents.

Eligibility Restrictions

Classification Populations Excluded or Restricted
Contraindication Individuals with known hypersensitivity or allergy to the active substance (diosmin/hesperidin) or any of the product’s excipients.
Age Restriction Children and adolescents under 18 years of age are excluded as the safety and efficacy of the medicine have not been established in this population.
Precautionary Avoidance Pregnant women: Use should be avoided as a precautionary measure due to the limited amount of human data available regarding use during pregnancy.
Not Recommended Breastfeeding women: Use is not recommended because it is unknown if the active substance or its metabolites are excreted into human milk, and a risk to the newborn cannot be ruled out.

Daflavon is generally authorized for use only in adults 18 years of age and older who do not meet any of the formal contraindication criteria. Patients with a documented allergy to any component of the medicine are formally ineligible for treatment.

What should I know about interactions with other medicines?

Daflavon Interactions with other medicines and products


Daflavon (a Micronized Purified Flavonoid Fraction, containing diosmin and hesperidin) has generally shown a favorable safety profile with no clinically significant drug interactions reported in major clinical trials or post-marketing surveillance for its primary use in venous disease and hemorrhoids.

However, due to the metabolic properties of its active ingredients, caution and professional consultation are advised when combining Daflavon with certain medications. The diosmin component may potentially influence the metabolism or transport of other drugs in the body.

Potential Moderate Interactions

Drug Category Potential Effect Recommendation
Anticoagulants (Blood Thinners) Increased risk of bleeding or bruising. Consult your doctor before combining; close monitoring may be required.
P-glycoprotein (P-gp) Substrates May increase the concentration and side effects of these drugs (e.g., fexofenadine). Inform your doctor of all medications to assess risk.

Always provide your healthcare provider (doctor or pharmacist) with a complete list of all medications, over-the-counter products, and herbal supplements you are currently taking. Do not start, stop, or adjust the dosage of any medicine without professional guidance. There are no specific restrictions related to food or alcohol consumption with Daflavon, but a discussion with your doctor is recommended.

Mechanism of Action

The Mechanism of Action of Daflavon

Daflavon operates through a dual-modulatory action targeting the microvasculature and related inflammatory pathways. Its compounds accumulate selectively in the vascular smooth muscle and endothelium of veins and capillaries.

Within the microvasculature, the compounds act as modulators to increase venous tone and reduce the hyperpermeability of capillaries. This physical stabilization of the vessel walls restricts the filtration of fluid from the bloodstream into the interstitial space. The resulting change is observed in the modulation of interstitial fluid dynamics.

Simultaneously, the drug acts as an antioxidant and enzyme inhibitor. It works to scavenge reactive oxygen species (ROS) and suppresses the activation of pro-inflammatory signaling cascades, notably the NF-kappaB pathway. By inhibiting the production of inflammatory mediators, the drug maintains the structural integrity of the vessels, preventing inflammation-driven cellular damage. The combination of vascular stabilization and anti-inflammatory activity constitutes the drug's overall mechanism.

Dosage and Administration Information

The use of Daflavon (Micronized Purified Flavonoid Fraction 500 mg) follows specific, labeled administration guidelines that differentiate between regimens for acute episodes and sustained symptomatic management. The medicine is consistently intended for oral administration as a film-coated tablet, which must be swallowed whole and taken at meal times. This timing is a key instruction for its proper administration.

The official dosing regimen is explicitly dependent on the clinical scenario:

Context Daily Dosing Regimen Duration Pattern
Sustained Symptomatic Management 2 tablets per day (1000 mg MPFF total), taken in two divided doses. Generally considered for sustained, long-term symptomatic support.
Acute Episodic Support Phase 1: 6 tablets daily for the first 4 days. Phase 2: 4 tablets daily for the subsequent 3 days. A structured, 7-day short course is specified for this regimen.

The total daily dose for either pattern is typically administered in divided doses throughout the day. An essential procedural constraint provided in prescribing documentation is that if an administration time is forgotten, a patient should not take a double dose to make up for the missed timing. Furthermore, its use is restricted to adults, as safety and dosage determination for the pediatric population (under 18 years) has not been formally established. This distinction in dosing and duration ensures standardized usage according to prescribing information.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Daflavon

Evidence for use in Persistent Fatigue

Research has explored use in conditions characterized by functional limitations using studies conducted over short time intervals, typically lasting between 4 and 8 weeks. These research scenarios explored short-term symptom changes by monitoring outcomes related to daily functioning or activity level and patient-reported outcomes describing perceived discomfort. Studies monitored measurements of self-reported fatigue scales when compared to control groups. Research highlights patterns of small or minimal reported differences between groups. Findings were mixed across the included studies regarding the magnitude of reported change in fatigue scores.

Evidence for use in Mild Cognitive Decline (MCD)

Daflavon was evaluated in research involving a population experiencing mild cognitive decline, a condition marked by functional limitations. Observational cohorts describe patterns related to associations between use and certain outcomes, but these patterns were not consistent. The short-to-mid-term randomized trials monitored reported changes, with some findings indicating inconsistent or small reported differences in global cognitive assessments between study groups at the end of the observed time intervals. The research provides context but not individual predictions about cognitive status.


What is Still Uncertain about Daflavon

Across all indications, the evidence is largely constrained by the structure of the studies. Sample sizes were modest, and follow-up durations were limited, contributing to a situation where evidence quality varies across studies and certainty remains low for long-term outcomes. The importance of the reported findings for daily life remains an area where certainty remains low. Few data are available for specific special populations, such as adolescents or individuals with severe chronic illnesses, meaning results apply only to the populations studied. More research is needed to fully characterize the evidence landscape and resolve inconsistencies.

Frequently Asked Questions (FAQ)

Common questions about Daflavon (FAQ)

Q: How quickly can someone expect to see improvement in leg heaviness after starting Daflavon?

A: Official research suggests that improvement in symptoms like leg heaviness and pain can begin within the first four weeks of starting treatment. Greater symptomatic benefit has been reported after approximately eight weeks of use in certain studies.


Q: Does Daflavon work for all stages of chronic venous insufficiency (CVI)?

A: Official product information suggests it is indicated for the treatment of symptoms related to chronic venous insufficiency. Clinical studies support its use for symptoms across various manifestations of the condition.


Q: Does Daflavon act as a blood thinner or increase the risk of bleeding?

A: Daflavon is not classified as an anticoagulant (blood thinner). However, the official labeling advises caution when it is used alongside other medicines that may affect bleeding or clotting, as these combinations should be professionally reviewed.


Q: How does the micronized formulation of Daflavon make it work better?

A: The micronized formulation process involves breaking the active compounds into very fine particles. This process is recognized for enhancing intestinal absorption, which is associated with better bioavailability of the active substances.


Q: What is the longest period of time someone can safely take Daflavon continuously?

A: For the ongoing management of chronic venous symptoms, use is generally considered for sustained periods. For hemorrhoid maintenance, use beyond two months should be reviewed by a healthcare professional to ensure continued appropriateness.


Q: Are there any specific foods or drinks that should be avoided while taking Daflavon?

A: No specific food or drink restrictions are listed in the official product information; however, consulting a healthcare professional about diet while on any medication is always advised.


Q: Does Daflavon have any known interactions with common vitamins or supplements?

A: Official documentation reports no known clinically relevant drug interaction with common vitamins or supplements. Nevertheless, always inform a healthcare provider of all products being taken.


Q: Will Daflavon help with both internal and external hemorrhoids?

A: Yes, Daflavon is indicated for the treatment of symptoms related to acute hemorrhoidal attacks. This generally applies to both internal and external forms of the condition.


Q: What's the difference between Daflavon 500 mg and Daflavon 1000 mg in terms of ingredients?

A: The 1000 mg tablet contains double the amount of the active substance, which is the Micronized Purified Flavonoid Fraction (MPFF). Both strengths contain the same proportion of active ingredients (90% Diosmin and 10% other flavonoids).


Q: Is Daflavon effective for preventing varicose veins from getting worse?

A: It is indicated for the treatment of symptoms related to venous circulation disorders, based on its venotonic action which assists in supporting microcirculation integrity.


Q: Does Daflavon interact with alcohol?

A: Official product documentation states there are no specific restrictions related to alcohol consumption; however, a discussion with a healthcare professional is recommended as general caution.


Q: Does Daflavon affect kidney function or liver function?

A: No specific studies have been performed for patients with pre-existing kidney or liver impairment. Official information suggests it should be taken with caution and under medical supervision if you have these conditions.


Q: Does Daflavon improve circulation in areas other than the legs and rectum?

A: Daflavon is a systemic venoactive drug; its mechanism of action targets microvasculature throughout the body. However, its approved regulatory indications are specific to treating symptoms related to venous insufficiency in the legs and acute hemorrhoidal attacks.


Q: Why is a healthy lifestyle (like walking and avoiding standing) still necessary while taking Daflavon?

A: Official guidance indicates that the medicine is most effective when combined with a healthy lifestyle. Recommendations include avoiding prolonged standing or excessive heat and using physical activity like walking to naturally stimulate blood circulation.


Q: How does Daflavon prevent fluid from leaking into surrounding tissues?

A: Daflavon works by stabilizing the vessel walls. It increases the tone of the veins and reduces the excessive permeability (leakiness) of the small capillaries, thereby restricting the filtration of fluid into the surrounding body tissues.


Q: Is the long-term safety of Daflavon well-established by clinical studies?

A: While the drug has a favorable short-term safety profile, official research summaries note that follow-up periods in many clinical studies have been limited. Consequently, certainty regarding very long-term outcomes remains low. Any continuous use should be periodically reviewed by a healthcare professional.


Q: Is it better to take Daflavon in the morning or at night?

A: Official administration instructions indicate the total daily dose is typically taken in two separate, divided portions, both at meal times.


Q: Can Daflavon be taken with pain relievers like ibuprofen or acetaminophen?

A: No clinically relevant drug interaction with common over-the-counter pain relievers has been widely reported. Nevertheless, official regulatory guidance always advises informing a doctor of all over-the-counter products before starting this medicine.


Q: Does Daflavon affect the effectiveness of birth control pills?

A: Based on post-marketing experience with the product, no clinically relevant interaction has been reported regarding birth control pills. You should still ensure your healthcare provider is aware of all medicines you are taking.


Q: Does Daflavon interact with any commonly prescribed antidepressant medications?

A: No clinically relevant drug interaction with antidepressants has been reported in post-marketing experience. You should still ensure your doctor is aware of all medicines you are taking.


Q: Can Daflavon be taken if a person is also on a daily low-dose aspirin regimen?

A: Caution is generally advised when combining Daflavon with any medicine that may affect bleeding, which includes aspirin. Consultation with a healthcare provider is necessary to assess individual circumstances.


Q: Does Daflavon interact with medications used for thyroid conditions?

A: No clinically relevant drug interaction regarding thyroid medications has been reported to date from post-marketing experience. You should always inform your doctor of all medicines you are currently taking.


Q: Can Daflavon be taken with other vein-supporting herbs like butcher's broom or horse chestnut?

A: Official guidance advises patients to always provide their healthcare provider with a complete list of all medications, over-the-counter products, and herbal supplements they are currently taking to check for potential risks.


Q: Is Daflavon safe to use for people with high blood pressure or on blood pressure medication?

A: High blood pressure or related medications are not listed as a contraindication or a specific interaction category in the official product information. However, consultation with a doctor is always advised when combining any medicines.


Q: Why is it important to consult a doctor if hemorrhoid symptoms don't improve quickly with Daflavon?

A: Treatment for an acute hemorrhoidal attack is intended to be short-term. Official guidance advises that if symptoms do not subside promptly, a medical examination is warranted.


Q: Can Daflavon help with restless legs syndrome if it's related to poor circulation?

A: Official product information indicates the medicine for symptoms of venolymphatic insufficiency, which includes 'restless legs'.


Q: Does Daflavon only treat symptoms, or does it improve the underlying vein health?

A: The medicine is indicated for the improvement of symptoms. However, its mechanism of action involves increasing venous tone and protecting microcirculation, which supports the structural integrity and health of the veins.

How should Daflavon be stored and disposed of?

How to Store and Dispose of Daflavon

Storage Requirements

Daflavon must be stored under specific conditions to maintain its stability, as defined by regulatory labeling. The medicine must be kept at a temperature below 30°C.

It is required to store the tablets in the original outer packaging. This serves to protect the product and maintain its quality. Furthermore, it is a mandatory safety instruction to keep Daflavon out of the sight and reach of children.

Shelf-Life

The medicine must not be used after the expiry date shown on the carton. The specified expiration date refers to the last day of the stated month.

Disposal Instructions

To prevent environmental contamination, Daflavon should not be disposed of via wastewater or ordinary household waste. You must consult a pharmacist to determine the appropriate procedure for discarding any unused or expired medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Daflavon found in:

A-Z Index: